How we transformed an Italian ophthalmic specialist into a global leader
SIFI is a clear example of our approach to supporting established businesses with strong foundations and significant growth potential. Through our investment, we helped strengthen the organization, expand international operations, and accelerate innovation across both pharmaceutical treatments and surgical solutions. These initiatives enabled the company to broaden its global reach, enter new markets, and further consolidate its position as a leading player in ophthalmology .
About the investment
Founded in 1935 in Italy, SIFI is a leading player in the ophthalmic industry, developing pharmaceutical treatments and surgical solutions for eye care.
At the time of 21 Invest’s investment in 2015, our approach was to build on the company’s unique combination of scientific expertise, established market presence and significant international growth potential.
Through a focused value creation strategy, we supported the strengthening of the organization, the expansion into new markets, and the acceleration of product innovation, helping transform SIFI into a leading international ophthalmic platform.
“When we invested in SIFI When we invested in SIFI ten years ago, we recognized the potential of an outstanding Italian company with a strong identity and ambitious international aspirations. Together with the Chines family and management team, we helped transform the company, enhancing its global footprint and innovation capabilities. Our commitment to long-term projects—such as the development of an orphan drug—embodies our philosophy: to invest responsibly, with value creation for all stakeholders at the center of our focus."
Alessandro Benetton, Founding Managing Partner, 21 Invest
How we added value
Recruitment of a CCO, CFO, country managers, as well as several other mid-management positions across the R&D, QRV and marketing departments.
We opened direct subsidiaries in Spain, France and Turkey, acquired a product portfolio in France and established JVs in China and Dubai.
In particular an orphan drug has been developed, that is now the only approved treatment for a very painful, potentially blinding and ultra rare eye disease, Akantameba Keratitis.
Key figures
+58%
Increase in sales
17
New Products Launch
+50%
Increased employees
65%
International revenues of total sales